Lithium Chloride Suppresses Colorectal Cancer Cell Survival and Proliferation through ROS/GSK-3 ss/NF-kappa B Signaling Pathway

Glycogen synthase kinase-3 beta (GSK-3 beta), a serine/threonine protein kinase, has been regarded as a potential therapeutic target for multiple human cancers. In addition, oxidative stress is closely related to all aspects of cancer. We sought to determine the biological function of lithium, one kind of GSK-3 beta. inhibitors, in the process of reactive oxygen species (ROS) production in colorectal cancer. In this study, we analyzed the cell apoptosis and proliferation by cell viability, EdU, and flow cytometry assays through administration of LiCl. We used polymerase chain reaction and Western blotting to establish the effect of GSK-3 beta. inhibition on the nuclear factor-kappa B (NF-kappa B) pathway. Results showed administration of LiCl increased apoptosis and the level of ROS in colorectal cancer cells. Furthermore, the underlying mechanisms could be mediated by the reduction of NF-kappa B expression and NF -kappa B-mediated transcription. Taken together, our results demonstrated that therapeutic targeting of ROS/GSK-3 beta/NF-kappa B pathways may be an effective way for colorectal cancer intervention, although further preclinical and clinical testing are desirable.